Protective effects of endomorphins, endogenous opioid peptides in the brain, on human low density lipoprotein oxidation

The FEBS Journal
Xin LinQiang Chen

Abstract

Neurodegenerative disorders are associated with oxidative stress. Low density lipoprotein (LDL) exists in the brain and is especially sensitive to oxidative damage. Oxidative modification of LDL has been implicated in the pathogenesis of neurodegenerative diseases. Therefore, protecting LDL from oxidation may be essential in the brain. The antioxidative effects of endomorphin 1 (EM1) and endomorphin 2 (EM2), endogenous opioid peptides in the brain, on LDL oxidation has been investigated in vitro. The peroxidation was initiated by either copper ions or a water-soluble initiator 2,2'-azobis(2-amidinopropane hydrochloride) (AAPH). Oxidation of the LDL lipid moiety was monitored by measuring conjugated dienes, thiobarbituric acid reactive substances, and the relative electrophoretic mobility. Low density lipoprotein oxidative modifications were assessed by evaluating apoB carbonylation and fragmentation. Endomorphins markedly and in a concentration-dependent manner inhibited Cu2+ and AAPH induced the oxidation of LDL, due to the free radical scavenging effects of endomorphins. In all assay systems, EM1 was more potent than EM2 and l-glutathione, a major intracellular water-soluble antioxidant. We propose that endomorphins provide p...Continue Reading

References

Oct 1, 1992·Free Radical Biology & Medicine·H EsterbauerG Jürgens
Sep 17, 1994·Lancet·P Jenner
Jan 1, 1994·Methods in Enzymology·N Noguchi, E Niki
Jan 1, 1996·Reviews of Physiology, Biochemistry and Pharmacology·H Esterbauer, P Ramos
May 15, 1996·Biochemical and Biophysical Research Communications·C PieriS Damjanovich
Jan 1, 1997·Free Radical Biology & Medicine·W R Markesbery
Jun 27, 1997·Brain Research·M SugawaO Cynshi
Aug 22, 1997·The Journal of Biological Chemistry·D Steinberg
Jan 1, 1997·Free Radical Biology & Medicine·M A LivreaM Morreale
May 5, 1998·Molecular and Chemical Neuropathology·B Draczynska-LusiakA Y Sun
Oct 14, 1998·Progress in Neurobiology·R J Reiter
Aug 17, 1999·Neurobiology of Disease·D J WaggonerJ D Gitlin
Apr 27, 2001·Biochemical Pharmacology·M FontanaM A Rosei
May 9, 2001·Biochimica Et Biophysica Acta·R CocciaM A Rosei
Aug 30, 2001·Journal of the Society for Gynecologic Investigation·M Berco, B R Bhavnani
Nov 24, 2001·Respiration Physiology·A P Wickens
Apr 30, 2002·Free Radical Biology & Medicine·M Flint Beal
Jul 11, 2002·Free Radical Biology & Medicine·Christian Behl, Bernd Moosmann
Jul 13, 2002·Annals of the New York Academy of Sciences·David S JessopMichael S Harbuz
Aug 3, 2002·Journal of Pineal Research·Dominique Bonnefont-RousselotMonique Gardès-Albert
Oct 24, 2002·Neurobiology of Aging·Robert A Floyd, Kenneth Hensley
Dec 18, 2002·Journal of Pineal Research·M AllegraM A Livrea
Feb 19, 2003·Clinica Chimica Acta; International Journal of Clinical Chemistry·Isabella Dalle-DonneRoberto Colombo

❮ Previous
Next ❯

Citations

Mar 22, 2008·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Shahid Husain, David E Potter
Sep 10, 2014·Environmental Toxicology and Pharmacology·Mamane SaniMossadok Ben-Attia
Aug 30, 2013·Canadian Journal of Physiology and Pharmacology·Peihan XuZheng Zhang
Aug 19, 2007·Chronobiology International·Mamane SaniMossadok Ben-Attia
Nov 9, 2007·Peptides·Weihong Pan, Abba J Kastin
Oct 24, 2007·Peptides·Richard J Bodnar
Feb 12, 2009·Journal of Peptide Science : an Official Publication of the European Peptide Society·Pin GongRui Wang

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.